Delaware
|
000-21326
|
04-3145961
|
(State or other jurisdiction of
|
Commission file number
|
(I.R.S. Employer
|
incorporation or organization)
|
|
Identification No.)
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered |
Common Stock, par value $0.01 per share
|
|
ANIK
|
|
NASDAQ Global Select Market
|
Anika Therapeutics, Inc. | |||
Dated: October 24, 2019
|
By:
|
/s/ Sylvia Cheung | |
Sylvia Cheung | |||
Chief Financial Officer | |||
Total Revenue Increases 11% and Net Income Increases 21% Year-over-Year
Company Raises Full Year 2019 Revenue and Earnings Guidance
Executing Five-Year Strategic Plan Focused on Joint Preservation and Restoration
BEDFORD, Mass.--(BUSINESS WIRE)--October 24, 2019--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (“HA”) technology platform, today reported financial results for the third quarter ended September 30, 2019 and provided an update on its business progress in the period.
“Anika delivered double-digit revenue and earnings growth in the third quarter on the strength of growing global demand, Anika’s expanding commercial platform, and continued fiscal discipline. The strength of our results in the third quarter is a testament to the hard work of the entire Anika team and reflects our continued progress towards executing our five-year strategic plan to transform Anika into a global commercial company focused on joint preservation and restoration,” said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics. “In the third quarter, we successfully completed the buildout of our hybrid commercial salesforce in the U.S., commenced the soft launch of TACTOSET under our hybrid commercial model and further strengthened our leadership team. We also continued to realize the benefits of our international expansion efforts, as evidenced by worldwide Orthobiologics revenue growth of 11% year-over-year for the quarter. We are confident we can continue to build on the momentum of our strong third quarter performance and accordingly, have raised our full year 2019 guidance. We look forward to continuing to drive financial and operational performance as we execute on our strategic plan to deliver growth and shareholder value.”
Third Quarter Financial Results
Recent Business Highlights
Full Year 2019 Revised Corporate Outlook
Non-GAAP Information
To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company is reporting Adjusted EBITDA, which is a non-GAAP financial measure and should not be considered an alternative to net income or other measurements under GAAP. The Company believes that Adjusted EBITDA provides additional useful information to investors in their assessment of its operating performance as it is a metric routinely used by management to evaluate the Company’s performance. Adjusted EBITDA is not calculated identically by all companies, and therefore the Company’s measurements of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. Adjusted EBITDA is defined by the Company as GAAP net income excluding depreciation and amortization, interest and other income (expense), income taxes and stock-based compensation expense. A reconciliation of Adjusted EBITDA to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, is shown in the table below for the three- and nine-month periods ended September 30, 2019 and 2018 (in thousands).
For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||||
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
|
|||||||
Net income |
$ |
9,200 |
|
$ |
7,599 |
|
$ |
23,142 |
|
$ |
11,004 |
|
||||||
Interest and other income, net |
|
(482 |
) |
|
(522 |
) |
|
(1,513 |
) |
|
(907 |
) |
||||||
Provision for income taxes |
|
3,331 |
|
|
1,496 |
|
|
7,817 |
|
|
1,890 |
|
||||||
Depreciation and amortization |
|
1,516 |
|
|
1,513 |
|
|
4,459 |
|
|
4,433 |
|
||||||
Stock-based compensation |
|
1,311 |
|
|
1,177 |
|
|
4,140 |
|
|
10,064 |
|
||||||
Adjusted EBITDA |
$ |
14,876 |
|
$ |
11,263 |
|
$ |
38,045 |
|
$ |
26,484 |
|
Conference Call Information
Anika’s management will hold a conference call and webcast to discuss its financial results and business highlights today, Thursday, October 24 at 5:00 pm ET. The conference call can be accessed by dialing 1-855-468-0611 (toll-free
domestic) or 1-484-756-4332 (international). A live audio webcast will be available in the "Investor Relations" section of Anika’s website, www.anikatherapeutics.com. An accompanying slide presentation may also be accessed via the Anika
website. A replay of the webcast will be available on Anika’s website approximately two hours after the completion of the event.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated joint preservation and regenerative therapies company based in Bedford, Massachusetts. Anika is committed to delivering therapies to improve the lives of patients across a
continuum of care from osteoarthritis pain management to joint preservation and restoration. The Company has over two decades of global expertise commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology
platform. For more information about Anika, please visit www.anikatherapeutics.com.
Forward-Looking Statements
The statements made in the second paragraph and in the section captioned “Full Year 2019 Revised Corporate Outlook” of this press release, which are not statements of historical fact, are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, those relating to the Company’s revised expectations with respect to
its 2019 financial performance. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks, uncertainties, and other factors. The Company’s actual results could differ
materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company’s ability to successfully commence
and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company’s ability to obtain pre-clinical or clinical data to support domestic and international pre-market approval applications, 510(k) applications, or
new drug applications, or to timely file and receive FDA or other regulatory approvals or clearances of its products; (iii) that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other
testing or regulatory submissions, as applicable; (iv) the Company’s research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (v) the
cost effectiveness and efficiency of the Company’s clinical studies, manufacturing operations, and production planning; (vi) the strength of the economies in which the Company operates or will be operating, as well as the political stability
of any of those geographic areas; (vii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (viii) the Company’s ability to successfully commercialize its products, in the U.S.
and abroad; (ix) quarterly sales volume variation experienced by the Company, which can make future results difficult to predict and period-to-period comparisons potentially less meaningful; (x) the Company’s ability to provide an adequate
and timely supply of its products to its customers; and (xi) the Company’s ability to achieve its growth targets. Additional factors and risks are described in the Company’s periodic reports filed with the Securities and Exchange Commission,
and they are available on the SEC’s website at www.sec.gov. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information
contained in this press release.
Anika Therapeutics, Inc. and Subsidiaries Consolidated Statements of Operations (in thousands, except per share data) (unaudited) |
|||||||||||||||||
For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||||
2019 |
2018 |
2019 |
2018 |
||||||||||||||
Product revenue |
$ |
29,615 |
$ |
26,781 |
$ |
84,745 |
|
$ |
78,581 |
|
|||||||
Licensing, milestone and contract revenue |
|
82 |
|
6 |
|
93 |
|
|
18 |
|
|||||||
Total revenue |
|
29,697 |
|
26,787 |
|
84,838 |
|
|
78,599 |
|
|||||||
Operating expenses: | |||||||||||||||||
Cost of product revenue |
|
5,951 |
|
8,282 |
|
20,098 |
|
|
24,279 |
|
|||||||
Research and development |
|
4,158 |
|
4,232 |
|
12,581 |
|
|
14,126 |
|
|||||||
Selling, general and administrative |
|
7,539 |
|
5,700 |
|
22,713 |
|
|
28,207 |
|
|||||||
Total operating expenses |
|
17,648 |
|
18,214 |
|
55,392 |
|
|
66,612 |
|
|||||||
Income from operations |
|
12,049 |
|
8,573 |
|
29,446 |
|
|
11,987 |
|
|||||||
Interest and other income, net |
|
482 |
|
522 |
|
1,513 |
|
|
907 |
|
|||||||
Income before income taxes |
|
12,531 |
|
9,095 |
|
30,959 |
|
|
12,894 |
|
|||||||
Provision for income taxes |
|
3,331 |
|
1,496 |
|
7,817 |
|
|
1,890 |
|
|||||||
Net income |
$ |
9,200 |
$ |
7,599 |
$ |
23,142 |
|
$ |
11,004 |
|
|||||||
Basic net income per share: | |||||||||||||||||
Net income |
$ |
0.65 |
$ |
0.53 |
$ |
1.65 |
|
$ |
0.76 |
|
|||||||
Basic weighted average common shares outstanding |
|
14,070 |
|
14,237 |
|
14,065 |
|
|
14,524 |
|
|||||||
Diluted net income per share: | |||||||||||||||||
Net income |
$ |
0.64 |
$ |
0.53 |
$ |
1.62 |
|
$ |
0.74 |
|
|||||||
Diluted weighted average common shares outstanding |
|
14,387 |
|
14,377 |
|
14,266 |
|
|
14,820 |
|
|||||||
Anika Therapeutics, Inc. and Subsidiaries | |||||||||||||||||
Consolidated Balance Sheets | |||||||||||||||||
(in thousands, except per share data) | |||||||||||||||||
(unaudited) | |||||||||||||||||
September 30, | December 31, | ||||||||||||||||
ASSETS |
2019 |
2018 |
|||||||||||||||
Current assets: | |||||||||||||||||
Cash, cash equivalents and investments |
$ |
173,206 |
|
$ |
159,014 |
|
|||||||||||
Accounts receivable, net |
|
23,889 |
|
|
20,775 |
|
|||||||||||
Inventories, net |
|
25,243 |
|
|
21,300 |
|
|||||||||||
Prepaid expenses and other current assets |
|
1,479 |
|
|
1,854 |
|
|||||||||||
Total current assets |
|
223,817 |
|
|
202,943 |
|
|||||||||||
Property and equipment, net |
|
51,750 |
|
|
54,111 |
|
|||||||||||
Right-of-use assets |
|
23,082 |
|
|
- |
|
|||||||||||
Other long-term assets |
|
5,761 |
|
|
4,897 |
|
|||||||||||
Intangible assets, net |
|
7,680 |
|
|
9,191 |
|
|||||||||||
Goodwill |
|
7,489 |
|
|
7,851 |
|
|||||||||||
Total assets |
$ |
319,579 |
|
$ |
278,993 |
|
|||||||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||||||||
Current liabilities: | |||||||||||||||||
Accounts payable |
$ |
2,702 |
|
$ |
3,143 |
|
|||||||||||
Accrued expenses and other current liabilities |
|
8,493 |
|
|
8,146 |
|
|||||||||||
Total current liabilities |
|
11,195 |
|
|
11,289 |
|
|||||||||||
Other long-term liabilities |
|
372 |
|
|
550 |
|
|||||||||||
Deferred tax liability |
|
4,727 |
|
|
3,542 |
|
|||||||||||
Lease liabilities |
|
21,603 |
|
|
- |
|
|||||||||||
Commitments and contingencies | |||||||||||||||||
Stockholders’ equity: | |||||||||||||||||
Preferred stock, $0.01 par value |
|
- |
|
|
- |
|
|||||||||||
Common stock, $0.01 par value |
|
143 |
|
|
142 |
|
|||||||||||
Additional paid-in-capital |
|
46,482 |
|
|
50,763 |
|
|||||||||||
Accumulated other comprehensive loss |
|
(6,318 |
) |
|
(5,526 |
) |
|||||||||||
Retained earnings |
|
241,375 |
|
|
218,233 |
|
|||||||||||
Total stockholders’ equity |
|
281,682 |
|
|
263,612 |
|
|||||||||||
Total liabilities and stockholders’ equity |
$ |
319,579 |
|
$ |
278,993 |
|
Anika Therapeutics, Inc. and Subsidiaries Supplemental Financial Data |
||||||||||||||||||||||||||
Revenue by Product Line and Product Gross Margin | ||||||||||||||||||||||||||
(in thousands, except percentages) | ||||||||||||||||||||||||||
(unaudited) | ||||||||||||||||||||||||||
For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||||||||||||
Product Line: |
|
2019 |
|
% |
|
2018 |
|
% |
|
2019 |
|
% |
|
2018 |
|
% |
||||||||||
Orthobiologics |
$ |
26,765 |
|
91 |
% |
$ |
24,097 |
|
90 |
% |
$ |
74,975 |
|
88 |
% |
$ |
69,778 |
|
88 |
% |
||||||
Surgical |
|
578 |
|
2 |
% |
|
1,191 |
|
4 |
% |
|
4,071 |
|
5 |
% |
|
3,700 |
|
5 |
% |
||||||
Dermal |
|
417 |
|
1 |
% |
|
80 |
|
1 |
% |
|
990 |
|
1 |
% |
|
163 |
|
1 |
% |
||||||
Other |
|
1,855 |
|
6 |
% |
|
1,413 |
|
5 |
% |
|
4,709 |
|
6 |
% |
|
4,940 |
|
6 |
% |
||||||
Product Revenue |
$ |
29,615 |
|
100 |
% |
$ |
26,781 |
|
100 |
% |
$ |
84,745 |
|
100 |
% |
$ |
78,581 |
|
100 |
% |
||||||
Product Gross Profit |
$ |
23,664 |
|
$ |
18,499 |
|
$ |
64,647 |
|
$ |
54,302 |
|
||||||||||||||
Product Gross Margin |
|
80% |
|
|
69% |
|
76% |
|
|
69% |
|
|||||||||||||||
Product Revenue by Geographic Region (in thousands, except percentages) (unaudited) |
||||||||||||||||||||||||||
For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||||||||||||
Geographic Region: |
|
2019 |
|
% |
|
2018 |
|
% |
|
2019 |
|
% |
|
2018 |
|
% |
||||||||||
United States |
$ |
23,437 |
|
79 |
% |
$ |
21,695 |
|
81 |
% |
$ |
66,462 |
|
78 |
% |
$ |
63,377 |
|
81 |
% |
||||||
Europe |
|
3,943 |
|
13 |
% |
|
3,132 |
|
12 |
% |
|
11,396 |
|
14 |
% |
|
9,021 |
|
11 |
% |
||||||
Other |
|
2,235 |
|
8 |
% |
|
1,954 |
|
7 |
% |
|
6,887 |
|
8 |
% |
|
6,183 |
|
8 |
% |
||||||
Product Revenue |
$ |
29,615 |
|
100 |
% |
$ |
26,781 |
|
100 |
% |
$ |
84,745 |
|
100 |
% |
$ |
78,581 |
|
100 |
% |
Anika Therapeutics, Inc.
Joseph Darling, President & CEO
Sylvia Cheung, CFO
Tel: 781-457-9000